New biomarker for synaptic function in Alzheimer's disease
2015
University of Gothenburg, Mölndal, Sweden
Alzheimer's disease affects several physiological processes of the central nervous system. Synaptic dysfunction and degeneration are one of the hallmarks of the pathology and it is thought to begin early in the disease. Neurogranin is a postsynaptic protein localized in several areas of the brain. It was shown that neurogranin is increased in cerebrospinal fluid in Alzheimer's disease. Here, cerebrospinal fluid and plasma samples from Alzheimer's disease patients were analyzed to investigate neurogranin as a biomarker of Alzheimer's disease. The results showed that there are unique neurogranin peptides only present in human plasma and not in cerebrospinal fluid, and vice versa. Neurogranin was significantly increased in cerebrospinal fluid of Alzheimer's patients, while plasma levels were similar and there was no correlation between neurogranin levels in both fluids. In this study, new plasma neurogranin peptides are described, which could be further investigated to be potential biomarker targets. Additionally, it is confirmed in human samples that neurogranin is increased in Alzheimer's disease and it could be further developed as a biomarker for synaptic function in neurodegenerative disorders.
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
Hlin Kvartsberg
Added on: 08-22-2021
[1] https://alzres.biomedcentral.com/articles/10.1186/s13195-015-0124-3[2] https://data.jrc.ec.europa.eu/dataset/a8fd26ef-b113-47ab-92ba-fd2be449c7eb
